Kiromic BioPharma Inc

NASDAQ:KRBP   1:09:01 PM EDT
0.30
+0.03 (+12.60%)
Products

Kiromic Biopharma Announces Company Will Directly Submit Amended Ind For Procel To The FDA In Second Half Of 2022

Published: 05/11/2022 11:02 GMT
Kiromic BioPharma Inc (KRBP) - Kiromic Biopharma Announces Company Will Directly Submit Amended Ind for Procel™ to the FDA in Second Half of 2022.
Kiromic Biopharma Inc - Type a FDA Meeting Will Not Be Pursued.
Kiromic Biopharma Inc - a Type a FDA Meeting Will Not Be Pursued.
Kiromic Biopharma Inc - Over Course of Last Ten Months, Has Developed a Plan to Address Previously Outlined Cmc Issues.